Structure Therapeutics (NASDAQ:GPCR) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS

Structure Therapeutics (NASDAQ:GPCR) issued its quarterly earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10), FiscalAI reports.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR traded up $0.52 on Friday, hitting $53.14. 329,459 shares of the company’s stock were exchanged, compared to its average volume of 558,888. The firm’s 50-day moving average is $47.63 and its 200 day moving average is $54.19. The company has a market capitalization of $3.78 billion, a PE ratio of -53.14 and a beta of -1.43. Structure Therapeutics has a 1-year low of $15.86 and a 1-year high of $94.90.

Analysts Set New Price Targets

GPCR has been the topic of a number of research reports. Citizens Jmp reduced their target price on shares of Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a report on Friday. Canaccord Genuity Group set a $111.00 price objective on Structure Therapeutics in a research note on Friday. HC Wainwright lowered their target price on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, June 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Finally, Wall Street Zen raised Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $110.91.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. PEAK6 LLC purchased a new stake in shares of Structure Therapeutics during the 4th quarter worth approximately $553,000. MML Investors Services LLC purchased a new position in shares of Structure Therapeutics in the 4th quarter valued at $544,000. Barclays PLC grew its position in shares of Structure Therapeutics by 107.6% in the 4th quarter. Barclays PLC now owns 7,833 shares of the company’s stock valued at $545,000 after buying an additional 4,060 shares during the last quarter. Stifel Financial Corp acquired a new stake in Structure Therapeutics during the 4th quarter worth $336,000. Finally, Envestnet Asset Management Inc. raised its stake in Structure Therapeutics by 14.5% during the 3rd quarter. Envestnet Asset Management Inc. now owns 12,220 shares of the company’s stock worth $342,000 after acquiring an additional 1,544 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.